Drug
Rozanolixizumab
Rozanolixizumab: highest development phase Post-Market, developed by UCB. 7 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- UCB
Trials
| Drug | Phase | Indication |
|---|---|---|
| Rozanolixizumab NCT07246564 | Post-Market | Myasthenia Gravis |
| Rozanolixizumab NCT07465289 | Phase 3 | Ocular Myasthenia Gravis |
| Rozanolixizumab NCT07463521 | Phase 3 | Ocular Myasthenia Gravis |
| rozanolixizumab NCT06540144 | Phase 3 | Generalized Myasthenia Gravis |
| Rozanolixizumab NCT05063162 | Phase 3 | Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) |
| rozanolixizumab NCT06149559 | Phase 2/3 | Generalized Myasthenia Gravis |
| rozanolixizumab NCT05643794 | Phase 2 | Fibromyalgia |
Latest
No recent events.
Follow Rozanolixizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.